A reappraisal on amyloid cascade hypothesis: the role of chronic infection in Alzheimer’s disease

References

• Mayeux R, Stern Y. Epidemiology of Alzheimer disease. Cold Spring Harb Perspect Med 2. 2012;2(8):a006239.
   PubMed Web of Science ®Google Scholar
• Sajjad R, Arif R, Shah AA, et al. Pathogenesis of Alzheimer’s disease: role of amyloid-beta and hyperphosphorylated tau protein. Pharm. Sci. 2018;80(4):581–591.
   Web of Science ®Google Scholar
• Sanabria-Castro A, Alvarado-Echeverría I, Monge-Bonilla C. Molecular pathogenesis of Alzheimer’s disease: an update. Ann Neurosci. 2017;24(1):46–54.
   PubMed Web of Science ®Google Scholar
• Bature F, Guinn B-A, Pang D, et al. Signs and symptoms preceding the diagnosis of Alzheimer’s disease: a systematic scoping review of literature from 1937 to 2016. BMJ Open. 2017;7(8):e015746.
   PubMed Web of Science ®Google Scholar
• Devanand DP. Viral hypothesis and antiviral treatment in Alzheimer’s disease. Curr Neurol Neurosci Rep. 2018;18(9):55.
   PubMed Web of Science ®Google Scholar
• Pisa D, Alonso R, Fernández-Fernández AM, et al. Polymicrobial infections in brain tissue from Alzheimer’s disease patients. Sci Rep. 2017;7(1):5559.
   PubMed Web of Science ®Google Scholar
• Fulop T, Witkowski JM, Bourgade K, et al. Can an infection hypothesis explain the beta amyloid hypothesis of Alzheimer’s Disease? Front Aging Neurosci. 2018;10:224.
   PubMed Web of Science ®Google Scholar
• Sochocka M, Sobczyński M, Sender-Janeczek A, et al. Association between periodontal health status and cognitive abilities. The role of cytokine profile and systemic inflammation. CAR. 2017;14(9):978–990.
   Web of Science ®Google Scholar
• Kocahan S, Doğan Z . Mechanisms of Alzheimer’s disease pathogenesis and prevention: the brain, neural pathology, n-methyl-d-aspartate receptors, tau protein and other risk factors. Clin Psychopharmacol Neurosci. 2017;15(1):1–8.
   PubMed Web of Science ®Google Scholar
• Kowalski K, Mulak A. Brain-gut-microbiota axis in Alzheimer’s disease. J Neurogastroenterol Motil. 2019;25(1):48–60.
   PubMed Web of Science ®Google Scholar
• Amon P, Sanderson I. What is the microbiome? Arch Dis Child Educ Pract Ed. 2017;102(5):257–260.
   PubMed Web of Science ®Google Scholar
• Jiang C, Li G, Huang P, et al. The gut microbiota and Alzheimer’s disease. J Alzheimers Dis. 2017;58(1):1–15.
   PubMed Web of Science ®Google Scholar
• Cani PD. Human gut microbiome: hopes, threats and promises. Gut. 2018;67(9):1716–1725.
   PubMed Web of Science ®Google Scholar
• Carabotti M, Scirocco A, Maselli MA, et al. The gut-brain axis: interactions between enteric microbiota, Central and enteric nervous systems. Ann Gastroenterol. 2015;28(2):203–209.
   PubMed Web of Science ®Google Scholar
• Bravo JA, Forsythe P, Chew MV, et al. Ingestion of lactobacillus strain regulates emotional behavior and Central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci U S A. 2011;108(38):16050–16055.
   PubMed Web of Science ®Google Scholar
• Erny D, Hrabě de Angelis AL, Jaitin D, et al. Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci. 2015;18(7):965–977.
   PubMed Web of Science ®Google Scholar
• Sonnenburg ED, Sonnenburg JL. Starving our microbial self: the deleterious consequences of a diet deficient in microbiota-accessible carbohydrates. Cell Metab. 2014;20(5):779–786.
   PubMed Web of Science ®Google Scholar
• Shi H, Wang Q, Zheng M, et al. Supplement of microbiota-accessible carbohydrates prevents neuroinflammation and cognitive decline by improving the gut microbiota-brain axis in diet-induced obese mice. J Neuroinflammation. 2020;17(1):77.
   PubMed Web of Science ®Google Scholar
• Bonaz B, Bazin T, Pellissier S. The vagus nerve at the interface of the Microbiota-Gut-Brain axis. Front Neurosci. 2018;12:49.
   PubMed Web of Science ®Google Scholar
• Farzi A, Fröhlich EE, Holzer P. Gut microbiota and the neuroendocrine system. Neurotherapeutics. 2018;15(1):5–22.
   PubMed Web of Science ®Google Scholar
• Alonso R, Pisa D, Fernández-Fernández AM, et al. Infection of fungi and bacteria in brain tissue from elderly persons and patients with Alzheimer’s Disease. Front Aging Neurosci. 2018;10:159.
   PubMed Web of Science ®Google Scholar
• Braniste V, Al-Asmakh M, Kowal C, et al. The gut microbiota influences blood-brain barrier permeability in mice. Sci Transl Med. 2014;6(263):263ra158.
   PubMed Web of Science ®Google Scholar
• Shen L, Liu L, Ji H-F . Alzheimer’s disease histological and behavioral manifestations in transgenic mice correlate with specific gut microbiome state. J Alzheimers Dis. 2017;56(1):385–390.
   PubMed Web of Science ®Google Scholar
• Vogt NM, Kerby RL, Dill-McFarland KA, et al. Gut microbiome alterations in Alzheimer’s disease. Sci Rep. 2017;7(1):13537.
   Web of Science ®Google Scholar
• Wu S-C, Cao Z-S, Chang K-M, et al . Intestinal microbial dysbiosis aggravates the progression of Alzheimer’s disease in Drosophila. Nat Commun. 2017;8(1):24.
   PubMed Web of Science ®Google Scholar
• Chen C, Ahn EH, Kang SS, et al. Gut dysbiosis contributes to amyloid pathology, associated with C/EBPβ/AEP signaling activation in Alzheimer’s disease mouse model. Sci Adv. 2020;6:eaba0466.
   PubMed Web of Science ®Google Scholar
• Kim M-S, Kim Y, Choi H, et al . Transfer of a healthy microbiota reduces amyloid and tau pathology in an Alzheimer’s disease animal model. Gut. 2020;69(2):283–294.
   PubMed Web of Science ®Google Scholar
• Dando SJ, Mackay-Sim A, Norton R, et al. Pathogens penetrating the Central nervous system: infection pathways and the cellular and molecular mechanisms of invasion. Clin Microbiol Rev. 2014;27(4):691–726.
   PubMed Web of Science ®Google Scholar
• Santiago-Tirado FH, Doering TL. False friends: phagocytes as trojan horses in microbial brain infections. PLoS Pathog. 2017;13(12):e1006680.
   PubMed Web of Science ®Google Scholar
• Banks WA, Gray AM, Erickson MA, et al. Lipopolysaccharide-induced blood-brain barrier disruption: roles of cyclooxygenase, oxidative stress, neuroinflammation, and elements of the neurovascular unit. J Neuroinflammation. 2015;12:223.
   PubMed Web of Science ®Google Scholar
• Kumar DKV, Choi SH, Washicosky KJ, et al . Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer’s disease. Sci Transl Med. 2016;8(340):340ra72.
   PubMed Web of Science ®Google Scholar
• White MR, Kandel R, Tripathi S, et al . Alzheimer’s associated β-amyloid protein inhibits influenza A virus and modulates viral interactions with phagocytes. PLoS One. 2014;9(7):e101364.
   PubMed Web of Science ®Google Scholar
• Cairns DM, Rouleau N, Parker RN, et al. A 3D human brain-like tissue model of herpes-induced Alzheimer’s disease. Sci Adv. 2020;6(19):eaay8828.
   PubMed Web of Science ®Google Scholar
• Ries M, Sastre M. Mechanisms of Aβ clearance and degradation by glial cells. Front Aging Neurosci. 2016;8:160.
   PubMed Web of Science ®Google Scholar
• Zhong L, Wang Z, Wang D, et al. Amyloid-beta modulates microglial responses by binding to the triggering receptor expressed on myeloid cells 2 (TREM2). Mol Neurodegener. 2018;13(1):15.
   PubMed Web of Science ®Google Scholar
• González-Reyes RE, Nava-Mesa MO, Vargas-Sánchez K, et al. Involvement of astrocytes in Alzheimer’s disease from a neuroinflammatory and oxidative stress perspective. Front Mol Neurosci. 2017;10:427.
   PubMed Web of Science ®Google Scholar
• Riviere GR, Riviere KH, Smith KS. Molecular and immunological evidence of oral Treponema in the human brain and their association with Alzheimer’s disease. Oral Microbiol. Immunol. 2002;17(2):113–118.
   PubMedGoogle Scholar
• Mann DMA, Tucker CM, Yates PO. Alzheimer’s disease: an olfactory connection? Mech Ageing Dev. 1988;42(1):1–15.
   PubMed Web of Science ®Google Scholar
• Leung JYK, Chapman JA, Harris JA, et al. Olfactory ensheathing cells are attracted to, and can endocytose, bacteria. Cell Mol Life Sci. 2008;65(17):2732–2739.
   PubMed Web of Science ®Google Scholar
• Musumeci T, Pellitteri R, Spatuzza M, et al. Nose-to-brain delivery: evaluation of polymeric nanoparticles on olfactory ensheathing cells uptake. J Pharm Sci. 2014;103(2):628–635.
   PubMed Web of Science ®Google Scholar
• Shoemark DK, Allen SJ. The microbiome and disease: reviewing the links between the oral microbiome, aging, and Alzheimer’s disease. J Alzheimers Dis. 2015;43(3):725–738.
   PubMed Web of Science ®Google Scholar
• Chen C-K, Wu Y-T, Chang Y-C . Association between chronic periodontitis and the risk of Alzheimer’s disease: a retrospective, population-based, matched-cohort study. Alzheimers Res Ther. 2017;9(1):56.
   PubMed Web of Science ®Google Scholar
• Tzeng N-S, Chung C-H, Yeh C-B, et al. Are chronic periodontitis and gingivitis associated with dementia? A nationwide, retrospective, Matched-Cohort study in Taiwan. Neuroepidemiology. 2016;47(2):82–93.
   PubMed Web of Science ®Google Scholar
• Chen J, Ren C-J, Wu L, et al. Tooth loss is associated with increased risk of dementia and with a Dose-Response Relationship. Front Aging Neurosci. 2018;10:415.
   PubMed Web of Science ®Google Scholar
• Nascimento PC, Castro MML, Magno MB, et al. Association between periodontitis and cognitive impairment in adults: a systematic review. Front Neurol. 2019;10:323.
   PubMed Web of Science ®Google Scholar
• Flemmig TF. Periodontitis. Ann Periodontol. 1999;4(1):32–38.
   PubMedGoogle Scholar
• Ilievski V, Zuchowska PK, Green SJ, et al. Chronic oral application of a periodontal pathogen results in brain inflammation, neurodegeneration and amyloid beta production in wild type mice. PLoS One. 2018;13(10):e0204941.
   PubMed Web of Science ®Google Scholar
• Hu Y, Li H, Zhang J, et al. Periodontitis induced by P. gingivalis-LPS is associated with neuroinflammation and learning and memory impairment in Sprague-Dawley rats. Front Neurosci. 2020;14:658.
   PubMed Web of Science ®Google Scholar
• Zhang J, Yu C, Zhang X, et al. Porphyromonas gingivalis lipopolysaccharide induces cognitive dysfunction, mediated by neuronal inflammation via activation of the TLR4 signaling pathway in C57BL/6 mice. J Neuroinflammation. 2018;15(1):37.
   PubMed Web of Science ®Google Scholar
• Kamer AR, Pushalkar S, Gulivindala D, et al. 2021. Periodontal dysbiosis associates with reduced CSF Aβ42 in cognitively normal elderly. Alzheimer’s Dement. 13:e12172.
   Web of Science ®Google Scholar
• Narengaowa Kong W, Lan F, Awan UF, et al. The oral-gut-brain AXIS: the influence of microbes in Alzheimer’s disease. Front. Cell. Neurosci. 2021;15:633735.
   PubMed Web of Science ®Google Scholar
• Kobayashi R, Ogawa Y, Hashizume-Takizawa T, et al. Oral bacteria affect the gut microbiome and intestinal immunity. Pathog Dis. 2020;78(3):ftaa024.
   PubMed Web of Science ®Google Scholar
• Feng Y-K, Wu Q-L, Peng Y-W, et al. Oral P. gingivalis impairs gut permeability and mediates immune responses associated with neurodegeneration in LRRK2 R1441G mice. J Neuroinflammation. 2020;17(1):347.
   PubMed Web of Science ®Google Scholar
• Engelman A, Cherepanov P. The structural biology of HIV-1: mechanistic and therapeutic insights. Nat Rev Microbiol. 2012;10(4):279–290.
   PubMed Web of Science ®Google Scholar
• Siliciano RF, Greene WC. HIV latency. Cold Spring Harb Perspect Med. 2011;1(1):a007096.
   PubMed Web of Science ®Google Scholar
• Bhatti AB, Usman M, Kandi V. Current scenario of HIV/AIDS, treatment options, and major challenges with compliance to antiretroviral Therapy. Cureus. 2016;8(3):e515.
   PubMedGoogle Scholar
• Ganser-Pornillos BK, Yeager M, Sundquist WI. The structural biology of HIV assembly. Curr Opin Struct Biol. 2008;18(2):203–217.
   PubMed Web of Science ®Google Scholar
• Turner BG, Summers MF. Structural biology of HIV. J Mol Biol. 1999;285(1):1–32.
   PubMed Web of Science ®Google Scholar
• Saylor D, Dickens AM, Sacktor N, et al. HIV-associated neurocognitive disorder-pathogenesis and prospects for treatment. Nat Rev Neurol. 2016;12(4):234–248.
   PubMed Web of Science ®Google Scholar
• Scutari R, Alteri C, Perno C, et al. The role of HIV infection in neurologic injury. Brain Sci. 2017;7(12):38.
   PubMed Web of Science ®Google Scholar
• Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69(18):1789–1799.
   PubMed Web of Science ®Google Scholar
• Valcour V, Chalermchai T, Sailasuta N, RV254/SEARCH 010 Study Group, et al. Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis. 2012;206(2):275–282.
   PubMed Web of Science ®Google Scholar
• Williams DW, Anastos K, Morgello S, et al. JAM-A AND ALCAM are therapeutic targets to inhibit diapedesis across the BBB of CD14+CD16+ monocytes in HIV-infected individuals. J Leukoc Biol. 2015;97(2):401–412.
   PubMed Web of Science ®Google Scholar
• Williams DW, Eugenin EA, Calderon TM, et al. Monocyte maturation, HIV susceptibility, and transmigration across the blood brain barrier are critical in HIV neuropathogenesis. J Leukoc Biol. 2012;91(3):401–415.
   PubMed Web of Science ®Google Scholar
• Veenstra M, León-Rivera R, Li M, et al. Mechanisms of CNS viral seeding by HIV + CD14+ CD16+ monocytes: establishment and reseeding of viral reservoirs contributing to HIV-Associated neurocognitive disorders. mBio. 2017a;8(5):e01280–17.
   PubMed Web of Science ®Google Scholar
• Veenstra M, Williams DW, Calderon TM, et al. Frontline science: CXCR7 mediates CD14 + CD16+ monocyte transmigration across the blood brain barrier: a potential therapeutic target for NeuroAIDS. J Leukoc Biol. 2017b;102(5):1173–1185.
   PubMed Web of Science ®Google Scholar
• Williams DW, Byrd D, Rubin LH, et al. CCR2 on CD14(+)CD16(+) monocytes is a biomarker of HIV-associated neurocognitive disorders. Neurol Neuroimmunol Neuroinflamm. 2014;1(3):e36.
   PubMedGoogle Scholar
• Anesten B, Yilmaz A, Hagberg L, et al. Blood-brain barrier integrity, intrathecal immunoactivation, and neuronal injury in HIV. Neurol Neuroimmunol Neuroinflamm. 2016;3(6):e300.
   PubMed Web of Science ®Google Scholar
• Anthony IC, Ramage SN, Carnie FW, et al. Accelerated tau deposition in the brains of individuals infected with human immunodeficiency virus-1 before and after the advent of highly active anti-retroviral therapy. Acta Neuropathol. 2006;111(6):529–538.
   PubMed Web of Science ®Google Scholar
• Cho Y-E, Lee M-H, Song B-J. Neuronal cell death and degeneration through increased nitroxidative stress and tau phosphorylation in HIV-1 transgenic rats. PLoS One. 2017;12(1):e0169945.
   PubMed Web of Science ®Google Scholar
• Kim J, Yoon J-H, Kim Y-S. HIV-1 tat interacts with and regulates the localization and processing of amyloid precursor protein. PLoS One. 2013;8(11):e77972.
   PubMed Web of Science ®Google Scholar
• Chen Y, Huang W, Jiang W, et al. HIV-1 tat regulates occludin and Aβ transfer receptor expression in brain endothelial cells via Rho/ROCK signaling pathway. Oxid Med Cell Longev. 2016;2016:4196572–4196579.
   PubMed Web of Science ®Google Scholar
• Jiang W, Huang W, Chen Y, et al. HIV-1 transactivator protein induces ZO-1 and neprilysin dysfunction in brain endothelial cells via the ras signaling pathway. Oxid Med Cell Longev. 2017;2017:3160360.
   PubMed Web of Science ®Google Scholar
• Bae M, Patel N, Xu H, et al. Activation of TRPML1 clears intraneuronal Aβ in preclinical models of HIV infection. J Neurosci. 2014;34(34):11485–11503.
   PubMed Web of Science ®Google Scholar
• Zou M, Huang W, Jiang W, et al. Role of cav-1 in HIV-1 Tat-Induced dysfunction of tight junctions and Aβ-Transferring Proteins. Oxid Med Cell Longev. 2019;2019:3403206–3403208.
   PubMed Web of Science ®Google Scholar
• Heaton RK, Franklin DR, Ellis RJ, HNRC Group, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011;17(1):3–16.
   PubMed Web of Science ®Google Scholar
• Kelly CM, van Oosterhout JJ, Ngwalo C, et al. HIV associated neurocognitive disorders (HAND) in malawian adults and effect on adherence to combination anti-Retroviral therapy: a cross sectional study. PLoS One. 2014;9(6):e98962.
   PubMed Web of Science ®Google Scholar
• Ances BM, Clifford DB. HIV-associated neurocognitive disorders and the impact of combination antiretroviral therapies. Curr Neurol Neurosci Rep. 2008;8(6):455–461.
   PubMed Web of Science ®Google Scholar
• Kinai E, Komatsu K, Sakamoto M, for HIV-Associated Neurocognitive Disorders in Japanese (J-HAND study group), et al. Association of age and time of disease with HIV-associated neurocognitive disorders: a Japanese nationwide multicenter study. J Neurovirol. 2017;23(6):864–874.
   PubMed Web of Science ®Google Scholar
• Merlini E, Iannuzzi F, Calcagno A, et al. Peripheral and cerebrospinal fluid immune activation and inflammation in chronically HIV-infected patients before and after virally suppressive combination antiretroviral therapy (cART). J Neurovirol. 2018;24(6):679–694.
   PubMed Web of Science ®Google Scholar
• Canet G, Dias C, Gabelle A, et al. HIV neuroinfection and Alzheimer’s disease: similarities and potential links?. Front Cell Neurosci. 2018;12:307.
   PubMed Web of Science ®Google Scholar
• Milanini B, Valcour V. Differentiating HIV-Associated neurocognitive disorders from Alzheimer’s Disease: an Emerging Issue in Geriatric NeuroHIV. Curr HIV/AIDS Rep. 2017;14(4):123–132.
   PubMed Web of Science ®Google Scholar
• Pulliam L, Sun B, Mustapic M, et al. Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer’s disease. J Neurovirol. 2019;25(5):702–709.
   PubMed Web of Science ®Google Scholar
• Brouillette M-J, Yuen T, Fellows LK, et al. Identifying neurocognitive decline at 36 months among HIV-Positive participants in the CHARTER cohort using Group-Based trajectory analysis. PLoS ONE. 2016;11(5):e0155766.
   PubMed Web of Science ®Google Scholar
• Sacktor N, Skolasky RL, Seaberg E, et al. Prevalence of HIV-associated neurocognitive disorders in the multicenter AIDS cohort study. Neurology. 2016;86(4):334–340.
   PubMed Web of Science ®Google Scholar
• Mäkitalo S, Mellgren Å, Borgh E, et al . The cerebrospinal fluid biomarker profile in an HIV-infected subject with Alzheimer’s disease. AIDS Res Ther. 2015;12:23.
   PubMed Web of Science ®Google Scholar
• Kumar SP, Chandy ML, Shanavas M, et al. Pathogenesis and life cycle of herpes simplex virus infection-stages of primary, latency and recurrence. J Oral Maxillofac Surg Med Pathol. 2016;28(4):350–353.
   Google Scholar
• Fatahzadeh M, Schwartz RA. Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis, and management. J Am Acad Dermatol. 2007;57(5):737–763.
   PubMed Web of Science ®Google Scholar
• Kukhanova MK, Korovina AN, Kochetkov SN. Human herpes simplex virus: life cycle and development of inhibitors. Biochemistry (Mosc). 2014;79(13):1635–1652.
   PubMed Web of Science ®Google Scholar
• Pilling A, Rosenberg MF, Willis SH, et al. Three-dimensional structure of herpes simplex virus type 1 glycoprotein D at 2.4-nanometer resolution. J Virol. 1999;73(9):7830–7834.
   PubMed Web of Science ®Google Scholar
• Mustafa M, Illzam E, Muniandy R, et al. Herpes simplex virus infections, pathophysiology and management. IOSR. 2016;15(07):85–91.
   Google Scholar
• Dauber B, Saffran HA, Smiley JR. The herpes simplex virus 1 virion host shutoff protein enhances translation of viral late mRNAs by preventing mRNA overload. J Virol. 2014;88(17):9624–9632.
   PubMed Web of Science ®Google Scholar
• Sadek J, Read GS. The splicing history of an mRNA affects its level of translation and sensitivity to cleavage by the virion host shutoff endonuclease during herpes simplex virus infections. J Virol. 2016;90(23):10844–10856.
   PubMed Web of Science ®Google Scholar
• Melchjorsen J, Matikainen S, Paludan SR. Activation and evasion of innate antiviral immunity by herpes simplex virus. Viruses. 2009;1(3):737–759.
   PubMed Web of Science ®Google Scholar
• Nicoll MP, Proença JT, Efstathiou S. The molecular basis of herpes simplex virus latency. FEMS Microbiol Rev. 2012;36(3):684–705.
   PubMed Web of Science ®Google Scholar
• Piacentini R, De Chiara G, Li Puma DD, et al . HSV-1 and Alzheimer’s disease: more than a hypothesis. Front Pharmacol. 2014;5:97.
   PubMed Web of Science ®Google Scholar
• Safieh M, Korczyn AD, Michaelson DM . ApoE4: an emerging therapeutic target for Alzheimer’s disease. BMC Med. 2019;17(1):64.
   PubMed Web of Science ®Google Scholar
• Itzhaki RF, Lin WR, Shang D, et al. Herpes simplex virus type 1 in brain and risk of Alzheimer’s disease. Lancet. 1997;349(9047):241–244.
   PubMed Web of Science ®Google Scholar
• De Chiara G, Marcocci ME, Civitelli L, et al. APP processing induced by herpes simplex virus type 1 (HSV-1) yields several APP fragments in human and rat neuronal cells. PLoS One. 2010;5(11):e13989.
   PubMed Web of Science ®Google Scholar
• Wozniak MA, Frost AL, Itzhaki RF. Alzheimer’s disease-specific tau phosphorylation is induced by herpes simplex virus type 1. J Alzheimers Dis. 2009;16(2):341–350.
   PubMed Web of Science ®Google Scholar
• Itzhaki RF. Corroboration of a major role for herpes simplex virus type 1 in alzheimer’s disease. Front. Aging Neurosci. 2018 Oct 19;10(324).doi:10.3389/fnagi.2018.00324.
   PubMed Web of Science ®Google Scholar
• Eimer WA, Vijaya Kumar DK, Navalpur Shanmugam NK, et al . Alzheimer’s disease-associated β-amyloid is rapidly seeded by herpesviridae to protect against brain infection. Neuron. 2018;99(1):56–63.e3.
   PubMed Web of Science ®Google Scholar
• De Chiara G, Racaniello M, Mollinari C, et al. Herpes simplex Virus-Type1 (HSV-1) impairs DNA repair in cortical Neurons. Front Aging Neurosci. 2016;8:242.
   PubMed Web of Science ®Google Scholar
• Alvarez G, Aldudo J, Alonso M, et al. Herpes simplex virus type 1 induces nuclear accumulation of hyperphosphorylated tau in neuronal cells. J Neurosci Res. 2012;90(5):1020–1029.
   PubMed Web of Science ®Google Scholar
• Civitelli L, Marcocci ME, Celestino I, et al . Herpes simplex virus type 1 infection in neurons leads to production and nuclear localization of APP intracellular domain (AICD): implications for Alzheimer’s disease pathogenesis. J Neurovirol. 2015;21(5):480–490.
   PubMed Web of Science ®Google Scholar
• Bourgade K, Le Page A, Bocti C, et al. Protective effect of amyloid-β peptides against herpes simplex virus-1 infection in a neuronal cell culture Model. J Alzheimers Dis. 2016;50(4):1227–1241.
   PubMed Web of Science ®Google Scholar
• Cohen C, Corpet A, Roubille S, et al. Promyelocytic leukemia (PML) nuclear bodies (NBs) induce latent/quiescent HSV-1 genomes chromatinization through a PML NB/histone H3.3/H3.3 chaperone axis. PLoS Pathog. 2018;14(9):e1007313.
   PubMed Web of Science ®Google Scholar
• Maroui MA, Callé A, Cohen C, et al. Latency entry of herpes simplex virus 1 is determined by the interaction of its genome with the nuclear Environment. PLoS Pathog. 2016;12(9):e1005834.
   PubMed Web of Science ®Google Scholar
• Jamieson GA, Maitland NJ, Wilcock GK, et al. Herpes simplex virus type 1 DNA is present in specific regions of brain from aged people with and without senile dementia of the Alzheimer type. J Pathol. 1992;167(4):365–368.
   PubMed Web of Science ®Google Scholar
• Jamieson GA, Maitland NJ, Craske J, et al . Detection of herpes simplex virus type 1 DNA sequences in normal and Alzheimer’s disease brain using polymerase chain reaction. Biochem Soc Trans. 1991;19(2):122S.
   PubMed Web of Science ®Google Scholar
• Hogestyn JM, Mock DJ, Mayer-Proschel M. Contributions of neurotropic human herpesviruses herpes simplex virus 1 and human herpesvirus 6 to neurodegenerative disease pathology. Neural Regen Res. 2018;13(2):211–221.
   PubMed Web of Science ®Google Scholar
• Corder E, Lannfelt L, Mulder M. Apolipoprotein E and herpes simplex virus 1 in Alzheimer’s disease. Lancet. 1998;352(9136):1312–1313.
   PubMed Web of Science ®Google Scholar
• Itzhaki RF . Herpes simplex virus type 1 and Alzheimer’s disease: increasing evidence for a major role of the virus. Front Aging Neurosci. 2014;6:202.
   PubMed Web of Science ®Google Scholar
• Lin W-R, Shang D, Wilcock GK, et al. Alzheimer’s disease, herpes simplex virus type 1, cold sores and apolipoprotein E4. Biochem Soc Trans. 1995;23(4):594S.
   PubMed Web of Science ®Google Scholar
• Tanaka S, Nagashima H . Establishment of an Alzheimer’s disease model with latent herpesvirus infection using PS2 and Tg2576 double transgenic mice. Exp Anim. 2018;67(2):185–192.
   PubMed Web of Science ®Google Scholar
• De Chiara G, Piacentini R, Fabiani M, et al. Recurrent herpes simplex virus-1 infection induces hallmarks of neurodegeneration and cognitive deficits in mice. PLoS Pathog. 2019;15(3):e1007617.
   PubMed Web of Science ®Google Scholar
• Bachmann NL, Polkinghorne A, Timms P. Chlamydia genomics: providing novel insights into chlamydial biology. Trends Microbiol. 2014;22(8):464–472.
   PubMed Web of Science ®Google Scholar
• Elwell C, Mirrashidi K, Engel J. Chlamydia cell biology and pathogenesis. Nat Rev Microbiol. 2016;14(6):385–400.
   PubMed Web of Science ®Google Scholar
• Grayston JT. Background and current knowledge of Chlamydia pneumoniae and atherosclerosis. J Infect Dis. 2000;181(Suppl 3):S402–S410.
   PubMed Web of Science ®Google Scholar
• Contini C, Seraceni S, Cultrera R, et al. Chlamydophila pneumoniae infection and its role in neurological disorders. Interdiscip Perspect Infect Dis. 2010;2010:273573.
   PubMedGoogle Scholar
• Balin BJ, Hammond CJ, Little CS, et al. Chlamydia pneumoniae: an etiologic agent for Late-Onset dementia. Front Aging Neurosci. 2018;10:302.
   PubMed Web of Science ®Google Scholar
• Porritt RA, Crother TR. Chlamydia pneumoniae infection and inflammatory diseases. For Immunopathol Dis Therap. 2016;7(3–4):237–254.
   PubMedGoogle Scholar
• Campbell LA, Kuo C. Chlamydia pneumoniae-an infectious risk factor for atherosclerosis? Nat Rev Microbiol. 2004;2(1):23–32.
   PubMed Web of Science ®Google Scholar
• Balin BJ, Gérard HC, Arking EJ, et al. Identification and localization of Chlamydia pneumoniae in the Alzheimer’s brain. Med Microbiol Immunol. 1998;187(1):23–42.
   PubMed Web of Science ®Google Scholar
• Hammond CJ, Hallock LR, Howanski RJ, et al . Immunohistological detection of Chlamydia pneumoniae in the Alzheimer’s disease brain. BMC Neurosci. 2010;11:121.
   PubMed Web of Science ®Google Scholar
• Itzhaki RF, Wozniak MA, Appelt DM, et al. Infiltration of the brain by pathogens causes Alzheimer’s disease. Neurobiol Aging. 2004;25(5):619–627.
   PubMed Web of Science ®Google Scholar
• Shima K, Kuhlenbäumer G, Rupp J. Chlamydia pneumoniae infection and Alzheimer’s disease: a connection to remember? Med Microbiol Immunol. 2010;199(4):283–289.
   PubMed Web of Science ®Google Scholar
• Higashijima M. Clinical study of respiratory function and difference in pneumonia history between Alzheimer’s Disease and Vascular Dementia Groups. J Phys Ther Sci. 2014;26(7):1113–1114.
   PubMedGoogle Scholar
• Lampela P, Tolppanen A-M, Tanskanen A, et al. Use of antidementia drugs and risk of pneumonia in older persons with Alzheimer’s disease. Ann Med. 2017;49(3):230–239.
   PubMed Web of Science ®Google Scholar
• MacIntyre A, Abramov R, Hammond CJ, et al. Chlamydia pneumoniae infection promotes the transmigration of monocytes through human brain endothelial cells. J Neurosci Res. 2003;71(5):740–750.
   PubMed Web of Science ®Google Scholar
• Little CS, Joyce TA, Hammond CJ, et al. Detection of bacterial antigens and Alzheimer’s disease-like pathology in the central nervous system of BALB/c mice following intranasal infection with a laboratory isolate of Chlamydia pneumoniae. Front Aging Neurosci. 2014;6:304.
   PubMed Web of Science ®Google Scholar
• Zelaya MV, Pérez-Valderrama E, de Morentin XM, et al. Olfactory bulb proteome dynamics during the progression of sporadic Alzheimer’s disease: identification of common and distinct olfactory targets across Alzheimer-related co-pathologies. Oncotarget. 2015;6(37):39437–56.
   PubMedGoogle Scholar
• Gérard HC, Dreses-Werringloer U, Wildt KS, et al . Chlamydophila (Chlamydia) pneumoniae in the Alzheimer’s brain. FEMS Immunol Med Microbiol. 2006;48(3):355–366.
   PubMedGoogle Scholar
• Little CS, Hammond CJ, MacIntyre A, et al. Chlamydia pneumoniae induces Alzheimer-like amyloid plaques in brains of BALB/c mice. Neurobiol Aging. 2004;25(4):419–429.
   PubMed Web of Science ®Google Scholar
• Lim C, Hammond CJ, Hingley ST, et al . Chlamydia pneumoniae infection of monocytes in vitro stimulates innate and adaptive immune responses relevant to those in Alzheimer’s disease. J Neuroinflammation. 2014;11:217.
   PubMed Web of Science ®Google Scholar
• Al-Atrache Z, Lopez DB, Hingley ST, et al. Astrocytes infected with Chlamydia pneumoniae demonstrate altered expression and activity of secretases involved in the generation of β-amyloid found in Alzheimer disease. BMC Neurosci. 2019;20(1):6.
   PubMed Web of Science ®Google Scholar
• Mäurer AP, Mehlitz A, Mollenkopf HJ, et al. Gene expression profiles of Chlamydophila pneumoniae during the developmental cycle and iron depletion-mediated persistence. PLoS Pathog. 2007;3(6):e83.
   PubMed Web of Science ®Google Scholar
• Faux NG, Rembach A, Wiley J, Ellis KA, Ames D, Fowler CJ, Martins RN, Pertile KK, Rumble RL, Trounson B, Masters CL; AIBL Research Group, Bush AI. An anemia of Alzheimer’s disease. Mol Psychiatry. 2014;19(11):1227–1234.
   PubMed Web of Science ®Google Scholar
• Motaleb MA, Liu J, Wooten RM. Spirochetal motility and chemotaxis in the natural enzootic cycle and development of lyme disease. Curr Opin Microbiol. 2015;28:106–113.
   PubMed Web of Science ®Google Scholar
• Wolgemuth CW. Flagellar motility of the pathogenic spirochetes. Semin Cell Dev Biol. 2015;46:104–112.
   PubMed Web of Science ®Google Scholar
• Tuddenham S, Ghanem KG. Neurosyphilis: knowledge gaps and controversies. Sex Transm Dis. 2018;45(3):147–151.
   PubMed Web of Science ®Google Scholar
• Gonzalez H, Koralnik IJ, Marra CM. Neurosyphilis. Semin Neurol. 2019;39(4):448–455.
   PubMed Web of Science ®Google Scholar
• Li W, Jiang M, Xu D, et al. Clinical and laboratory characteristics of symptomatic and asymptomatic neurosyphilis in HIV-Negative patients: a retrospective study of 264 cases. BioMed Res Int. 2019;2019:1–6.
   Web of Science ®Google Scholar
• Schwenkenbecher P, Pul R, Wurster U, et al. Common and uncommon neurological manifestations of neuroborreliosis leading to hospitalization. BMC Infect Dis. 2017;17(1):90.
   PubMed Web of Science ®Google Scholar
• Lamichhane J, Haider R, Bekkerman M, et al. A case of undetected neuroborreliosis in a 75-Year-Old chinese Male. Case Rep Infect Dis. 2018;2018:6764894.
   PubMed Web of Science ®Google Scholar
• Blanc F, Philippi N, Cretin B, et al. Lyme neuroborreliosis and dementia. J Alzheimers Dis. 2014;41(4):1087–1093.
   PubMed Web of Science ®Google Scholar
• Kristoferitsch W, Aboulenein-Djamshidian F, Jecel J, et al. Secondary dementia due to lyme neuroborreliosis. Wien Klin Wochenschr. 2018;130(15–16):468–478.
   PubMed Web of Science ®Google Scholar
• Topakian R, Artemian H, Metschitzer B, et al. Dramatic response to a 3-week course of ceftriaxone in late neuroborreliosis mimicking atypical dementia and normal pressure hydrocephalus. J Neurol Sci. 2016;366:146–148.
   PubMed Web of Science ®Google Scholar
• Allen HB. Alzheimer’s disease: a novel hypothesis for the development and the subsequent role of beta amyloid. J Neuroinfect Dis. 2016;7(2):1000211.
   Google Scholar
• Miklossy J . Alzheimer’s disease - a neurospirochetosis. Analysis of the evidence following Koch’s and Hill’s criteria. J Neuroinflammation. 2011;8:90.
   PubMed Web of Science ®Google Scholar
• Shin OS. Insight into the pathogenesis of lyme disease. J Bacteriol Virol. 2014;44(1):10.
   Google Scholar
• Di Domenico EG, Cavallo I, Bordignon V, et al. The emerging role of microbial biofilm in lyme Neuroborreliosis. Front Neurol. 2018;9:1048.
   PubMed Web of Science ®Google Scholar
• Rutherford ST, Bassler BL. Bacterial quorum sensing: its role in virulence and possibilities for its control. Cold Spring Harb Perspect Med 2. 2012;2(11):a012427–a012427.
   PubMed Web of Science ®Google Scholar
• Sapi E, Balasubramanian K, Poruri A, et al. Evidence of in vivo existence of borrelia biofilm in borrelial lymphocytomas. Eur J Microbiol Immunol (Bp). 2016;6(1):9–24.
   PubMedGoogle Scholar
• Miklossy J. Bacterial amyloid and DNA are important constituents of senile plaques: further evidence of the spirochetal and biofilm nature of senile Plaques. J Alzheimers Dis. 2016;53(4):1459–1473.
   PubMed Web of Science ®Google Scholar
• Mehrabian S, Raycheva M, Traykova M, et al. Neurosyphilis with dementia and bilateral hippocampal atrophy on brain magnetic resonance imaging. BMC Neurol. 2012;12:96.
   PubMed Web of Science ®Google Scholar
• Mehrabian S, Raycheva MR, Petrova EP, et al. Neurosyphilis presenting with dementia, chronic chorioretinitis and adverse reactions to treatment: a case report. Cases J. 2009;2:8334.
   PubMedGoogle Scholar
• Mayer FL, Wilson D, Hube B. Candida albicans pathogenicity mechanisms. Virulence. 2013;4(2):119–128.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007;20(1):133–163.
   PubMed Web of Science ®Google Scholar
• McManus BA, Coleman DC. Molecular epidemiology, phylogeny and evolution of Candida albicans. Infect Genet Evol. 2014;21:166–178.
   PubMed Web of Science ®Google Scholar
• Tyc KM, Kühn C, Wilson D, et al. Assessing the advantage of morphological changes in Candida albicans: a game theoretical study. Front Microbiol. 2014;5:41.
   PubMed Web of Science ®Google Scholar
• Sudbery P, Gow N, Berman J. The distinct morphogenic states of Candida albicans. Trends Microbiol. 2004;12(7):317–324.
   PubMed Web of Science ®Google Scholar
• Tsui C, Kong EF, Jabra-Rizk MA. Pathogenesis of Candida albicans biofilm. Pathog Dis. 2016;74(4):ftw018.
   PubMed Web of Science ®Google Scholar
• Alonso R, Pisa D, Marina AI, et al. Evidence for fungal infection in cerebrospinal fluid and brain tissue from patients with amyotrophic lateral sclerosis. Int J Biol Sci. 2015;11(5):546–558.
   PubMed Web of Science ®Google Scholar
• Pisa D, Alonso R, Rábano A, et al. Different brain regions are infected with fungi in Alzheimer’s Disease. Sci Rep. 2015;5:15015.
   PubMed Web of Science ®Google Scholar
• Jong AY, Stins MF, Huang SH, et al. Traversal of Candida albicans across human blood-brain barrier in vitro. Infect Immun. 2001;69(7):4536–4544.
   PubMed Web of Science ®Google Scholar
• Liu Y, Mittal R, Solis NV, et al. Mechanisms of Candida albicans trafficking to the brain. PLoS Pathog. 2011;7(10):e1002305.
   PubMed Web of Science ®Google Scholar
• Wu W-K, Chen C-C, Panyod S, et al . Optimization of fecal sample processing for microbiome study - the journey from bathroom to bench. J Formos Med Assoc. 2019;118(2):545–555.
   PubMed Web of Science ®Google Scholar
• Minter MR, Zhang C, Leone V, et al . Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer’s disease. Sci Rep. 2016;6:30028.
   PubMed Web of Science ®Google Scholar
• Minter MR, Hinterleitner R, Meisel M, et al . Antibiotic-induced perturbations in microbial diversity during post-natal development alters amyloid pathology in an aged APPSWE/PS1ΔE9 murine model of Alzheimer’s disease. Sci Rep. 2017;7(1):10411.
   PubMed Web of Science ®Google Scholar
• Dodiya HB, Frith M, Sidebottom A, et al . Synergistic depletion of gut microbial consortia, but not individual antibiotics, reduces amyloidosis in APPPS1-21 Alzheimer’s transgenic mice. Sci Rep. 2020;10(1):8183.
   PubMed Web of Science ®Google Scholar
• Loeb MB, Molloy DW, Smieja M, et al . A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer’s disease. J Am Geriatr Soc. 2004;52(3):381–387.
   PubMed Web of Science ®Google Scholar
• Balducci C, Santamaria G, La Vitola P, et al . Doxycycline counteracts neuroinflammation restoring memory in Alzheimer’s disease mouse models. Neurobiol Aging. 2018;70:128–139.
   PubMed Web of Science ®Google Scholar
• Qosa H, Abuznait AH, Hill RA, et al. Enhanced brain amyloid-β clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer’s disease. JAD. 2012;31(1):151–165.
   Web of Science ®Google Scholar
• Dominy SS, Lynch C, Ermini F, et al . Porphyromonas gingivalis in Alzheimer’s disease brains: evidence for disease causation and treatment with small-molecule inhibitors. Sci Adv. 2019;5(1):eaau3333.
   PubMed Web of Science ®Google Scholar
• Hui Z, Zhijun Y, Yushan Y, et al . The combination of acyclovir and dexamethasone protects against Alzheimer’s disease-related cognitive impairments in mice. Psychopharmacology (Berl). 2020;237(6):1851–1860.
   PubMed Web of Science ®Google Scholar
• Devanand DP, Andrews H, Kreisl WC, et al. Antiviral therapy: valacyclovir treatment of Alzheimer’s Disease (VALAD) Trial: protocol for a randomised, double-blind, placebo-controlled, treatment trial. BMJ Open. 2020;10(2):e032112.
   PubMed Web of Science ®Google Scholar
• Wozniak MA, Frost AL, Preston CM, et al. Antivirals reduce the formation of key Alzheimer’s disease molecules in cell cultures acutely infected with herpes simplex virus type 1. PLOS One. 2011;6(10):e25152.
   PubMed Web of Science ®Google Scholar
• Wozniak MA, Frost AL, Itzhaki RF . The helicase-primase inhibitor Bay 57-1293 reduces the Alzheimer’s disease-related molecules induced by herpes simplex virus type 1. Antiviral Res. 2013;99(3):401–404.
   PubMed Web of Science ®Google Scholar
• Kim KO, Gluck M. Fecal microbiota transplantation: an update on clinical Practice. Clin Endosc. 2019;52(2):137–143.
   PubMed Web of Science ®Google Scholar
• Khanna S, Vazquez-Baeza Y, González A, et al. Changes in microbial ecology after fecal microbiota transplantation for recurrent C. difficile infection affected by underlying inflammatory bowel disease. Microbiome. 2017;5(1):55.
   PubMed Web of Science ®Google Scholar
• Wang J, Li X, Wu X, et al. Fecal microbiota transplantation as an effective treatment for Carbapenem-Resistant Klebsiella pneumoniae infection in a renal transplant Patient. Infect Drug Resist. 2021;14:1805–1811.
   PubMed Web of Science ®Google Scholar
• Gouveia C, Palos C, Pereira P, et al. Fecal microbiota transplant in a patient infected with Multidrug-Resistant bacteria: a case Report. GE Port J Gastroenterol. 2020;28(1):56–61.
   PubMedGoogle Scholar
• Vendrik KEW, Ooijevaar RE, de Jong PRC, et al. Fecal microbiota transplantation in neurological disorders. Front Cell Infect Microbiol. 2020;10:98.
   PubMed Web of Science ®Google Scholar
• Kang D-W, Adams JB, Gregory AC, et al. Microbiota transfer therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome. 2017;5(1):10.
   PubMed Web of Science ®Google Scholar
• Kang D-W, Adams JB, Coleman DM, et al. Long-term benefit of microbiota transfer therapy on autism symptoms and gut microbiota. Sci Rep. 2019;9(1):5821.
   PubMed Web of Science ®Google Scholar
• Sun J, Xu J, Ling Y, et al. Fecal microbiota transplantation alleviated Alzheimer’s disease-like pathogenesis in APP/PS1 transgenic mice. Transl Psychiatry. 2019;9(1):13.
   PubMed Web of Science ®Google Scholar
• Hazan S . Rapid improvement in Alzheimer’s disease symptoms following fecal microbiota transplantation: a case report. J Int Med Res. 2020;48(6):300060520925930.
   PubMed Web of Science ®Google Scholar